Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina

dc.creatorSosa-Estani, Sergio
dc.creatorSegura, Elsa L.
dc.date2020-11-25T13:56:26Z
dc.date2020-11-25T13:56:26Z
dc.date1999
dc.date.accessioned2023-08-29T20:07:16Z
dc.date.available2023-08-29T20:07:16Z
dc.identifier1678-8060
dc.identifierhttp://sgc.anlis.gob.ar/handle/123456789/1739
dc.identifier10.1590/s0074-02761999000700070
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8519569
dc.descriptionFil: Sosa Estani, Sergio. ANLIS Dr.C.G.Malbrán. Centro Nacional de Diagnóstico e Investigación de Endemo-Epidemias; Argentina.
dc.descriptionFil: Segura, Elsa Leonor. ANLIS Dr.C.G.Malbrán. Centro Nacional de Diagnóstico e Investigación de Endemo-Epidemias; Argentina.
dc.descriptionThe goals of specific treatment against Trypanosoma cruzi infection, at an individual level, are to eliminate the parasite, to diminish the probability of developing illness (Chagas disease), and to hinder the chain of T. cruzi transmission as actions for the control of vectorial and non vectorial transmission (Sosa Estani 1993). Around 1930, investigations began in Argentina to obtain an effective drug against T. cruzi. Of all the substances evaluated, only nifurtimox (1972) and benznidazol (1974) have been accepted by the Ministry of Health as anti-T. cruzi drugs. Both drugs began to be assessed on the acute phase, and later, on the chronic phase of the disease
dc.formatpdf
dc.languageen
dc.relationMemorias do Instituto Oswaldo Cruz
dc.rightsopen
dc.sourceMemorias do Instituto Oswaldo Cruz 1994; 94(1):363-365
dc.subjectTrypanosoma cruzi
dc.subjectTerapéutica
dc.subjectArgentina
dc.titleTreatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina
dc.typeArtículo


Este ítem pertenece a la siguiente institución